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ARTICLE
YAP1/TAZ drives ependymoma-like tumour
formation in mice
Noreen Eder1,2, Federico Roncaroli3, Marie-Charlotte Dolmart4, Stuart Horswell5, Felipe Andreiuolo6,
Helen R. Flynn2, Andre T. Lopes1, Suzanne Claxton1, John-Paul Kilday7, Lucy Collinson4, Jun-Hao Mao8,
Torsten Pietsch6, Barry Thompson9, Ambrosius P. Snijders2 & Sila K. Ultanir1✉
YAP1 gene fusions have been observed in a subset of paediatric ependymomas. Here we
show that, ectopic expression of active nuclear YAP1 (nlsYAP5SA) in ventricular zone neural
progenitor cells using conditionally-induced NEX/NeuroD6-Cre is sufficient to drive brain
tumour formation in mice. Neuronal differentiation is inhibited in the hippocampus. Deletion
of YAP1’s negative regulators LATS1 and LATS2 kinases in NEX-Cre lineage in double con-
ditional knockout mice also generates similar tumours, which are rescued by deletion of YAP1
and its paralog TAZ. YAP1/TAZ-induced mouse tumours display molecular and ultra-
structural characteristics of human ependymoma. RNA sequencing and quantitative pro-
teomics of mouse tumours demonstrate similarities to YAP1-fusion induced supratentorial
ependymoma. Finally, we find that transcriptional cofactor HOPX is upregulated in mouse
models and in human YAP1-fusion induced ependymoma, supporting their similarity. Our
results show that uncontrolled YAP1/TAZ activity in neuronal precursor cells leads to
ependymoma-like tumours in mice.
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Yes-associated protein 1 (YAP1) is a transcriptional reg-ulator with oncogenic activity that is involved in cellularproliferation, maintenance of stem cell properties and
tumorigenesis1. YAP1 activity is the output of the conserved
hippo signalling pathway, which is implicated in cancer2–4. This
canonical kinase signalling system/pathway transmits mechanical
stimuli from the cell surface to regulate cell proliferation, survival
and tissue size in multiple organs across species1,5–8. The core
kinase cascade consists of the Hippo kinase in Drosophila and its
homologue Mammalian Sterile 20-like 1 (MST1) and MST2 in
mammals, together with hippo’s downstream effector Warts in
Drosophila, which is homologous to the Large tumour suppressor
homologue 1 (LATS1) and LATS2 kinases in mammals9. MST1/2
phosphorylates and activate LATS1/2, which in turn phosphor-
ylates to inhibit YAP1 or its close homologue TAZ/WWTR1.
YAP1 phosphorylation promotes its degradation via 14-3-3 bind-
ing and cytoplasmic sequestering, preventing its translocation to
the nucleus10. YAP1 activates TEAD1-4-dependent gene expres-
sion, which is required for its effects on cellular proliferation11–14.
The role of hippo signalling in mammalian tumorigenesis has been
demonstrated in vivo, for example, by conditional deletion of
MST1/2 or LATS1/2 in liver, which deregulates progenitor cell
proliferation and leads to tumorigenesis in mice15–17. Moreover,
activated YAP1 expression has been shown to drive embryonal
rhabdomyosarcoma formation18, whereas its expression in several
cancer types makes YAP1 a considered target for novel treat-
ments19. However, its role in brain tumours, such as ependymoma,
is not fully described.
Ependymoma is the third most common paediatric brain
tumour. It accounts for 5–10% of all primary tumours of the
central nervous system (CNS) in children and adolescents20–23.
Ependymomas have recently been classified into nine molecular
subgroups based on genetic and epigenetic profiles, age of onset
and location (supratentorial, posterior fossa and spinal)24,25.
Surgery followed by radiotherapy are the main treatment mod-
alities for most patients24,26–28. Recurrence rates are however high
and up to 40% of ependymomas are incurable24,27. Approximately
70% of supratentorial ependymomas are characterised by a fusion
between C11ORF95 and RELA29,30, whereas ~4–10% carry the
fusions of YAP1 with other genes encoding transcription factors:
YAP1-MAMLD1, or YAP1-FAM118B29,31,32. The group of
ependymomas with YAP1 fusions occurs almost exclusively in
children24.
Ependymomas likely originate from a restricted population of
radial glial-like stem cells that are found in the ventricles and
spinal canal of embryos and adults33. Radial glia and intermediate
neural progenitors derived from them normally produce neurons,
oligodendrocytes, astrocytes and ependymal cells34–38. Signalling
mechanisms that normally regulate cellular progenitor prolifera-
tion and orchestrate differentiation are therefore strong candi-
dates to be involved in paediatric tumourigenesis. YAP1 is
present in the embryonic ventricular zone and later in the
ependyma of mice39,40 where it has been implicated in ependymal
cell differentiation40.
We use conditional mouse models of active YAP1 expression
and LATS1/2 deletion and show that suppression of YAP1 activity
in NEX/NeuroD6 expressing neuronal precursor cells is essential
for limiting proliferation and enabling neuronal differentiation in
the brain, whereas activation of YAP1 is sufficient to produce
tumours that display features similar to human ependymoma.
Results
Active YAP1 expression in NEX-Cre lineage induces tumours.
Whether or not elevated YAP1 activity is tumourigenic in the
developing mammalian brain is an open question. To target for cell
types that normally express YAP1 in a developing brain, we first
examined YAP1 localisation in mice brains using immunohis-
tochemistry (IHC) with a specific anti-YAP1 antibody. YAP1 was
highly expressed in the ventricular zone (VZ) at postnatal day 0
(P0) (Fig. 1a, Supplementary Fig. 1a), becoming localised in the
ependymal layer at P20 (Supplementary Fig. 1a)41. A subset of
YAP1-positive cells in the VZ at P0 was mitotically active and were
of radial glial origin as shown by Ki67 and nestin co-expression,
respectively (Fig. 1b, c). NEX-Cre positive neuronal precursor cells
(NPCs) are known to be generated in the VZ starting at E11.5 and
NEX/Math2/NeuroD6 lineage gives rise to pyramidal neurons of
the cortex and hippocampus but does not contribute to astrocytes
or oligodendrocytes42,43. We crossed NEX-Cre-expressing mice
with a Rosa26-tdTomato mouse reporter line44. In addition to
pyramidal neurons, we observed numerous tdTomato expressing
cells in the VZ at P0 (Supplementary Fig. 1b–d). This finding is in
agreement with previous reports showing NEX-Cre in dividing
NPCs42. TdTomato reporter positive cells also expressed YAP1,
indicating that NEX-Cre driver can be used to manipulate a sub-
population of neural precursor cells (Supplementary Fig. 1b–d).
Based on this evidence, we assessed the effect of uncontrollable
YAP1 activity in NEX-expressing NPCs, by using a Cre inducible
mouse model, in which a hyperactive form of YAP1, nlsYAP5SA,
is preceded by a floxed STOP codon45. Upon Cre-mediated
recombination these transgenic mice express phosphomutant
YAP1 (S61A, S109A, S127A, S164A, S381A), which cannot be
phosphorylated and inhibited by kinases, such as LATS1/246. In
addition, nlsYAP5SA contains a nuclear localisation signal (nls)
to direct YAP1 activity to the nucleus. nlsYAP5SA; NEX-Cre
mice (Fig. 1d) displayed multiple subependymal tumours at P14
along the lateral ventricles as well as in cerebellum (Fig. 1e). These
results indicate that uncontrolled YAP1 in NEX-Cre lineage is
sufficient for tumour formation.
nlsYAP5SA suppresses hippocampal neuron differentiation.
We next determined the progression of the tumour formation at
earlier developmental stages. In nlsYAP5SA; NEX-Cre mice,
nuclear YAP1 was expressed throughout neocortex and hippo-
campus (Fig. 2a). In these animals, hippocampal neuronal cell
body layers (CA1, CA3 and dentate gyrus) showed neuronal loss
and disruption of normal layering as observed with the neuronal
markers NeuN and CTIP2 (Fig. 2a, Supplementary Fig. 2a, b). We
also identified multiple tumours adjacent to the ependymal layer
(Fig. 2b). These tumours were positive for nestin, indicating that
constitutive cells are of neuronal stem cell specification (Fig. 2c).
Tumours did not express NeuN indicating that the tumour did
not contain differentiated neurons, but several cells within the
tumour mass expressed Ki67, a marker of proliferation, indicating
that the tumours contain actively dividing cells (Fig. 2c). These
data show that sustained nuclear YAP1 in NEX-Cre expressing
NPCs lead to tumour formation by maintaining a neural stem
cell-like fate and preventing hippocampal pyramidal neuronal
differentiation.
Deletion of LATS1/2 in NEX-Cre lineage causes brain tumours.
Despite several lines of evidence that supports an oncogenic role
for YAP1, the impact of kinases regulating YAP1 activity in cancer
is not well understood. In mammals, the canonical upstream
phosphorylation and suppression of YAP1/TAZ activity is pre-
dominantly accomplished by two homologous kinases, LATS1 and
LATS2. Constitutive knockout of LATS2 results in embryonic
lethality47, whereas constitutive LATS1 knockout leads to soft
tissue sarcoma and ovarian tumour development48, indicating
essential roles of LATS2 during development and compensatory
roles between the homologues. Conditional knockout of LATS1
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and LATS2 (LATS1/2) in mouse liver increases proliferation and
represses the maturation of hepatocytes thereby causing pre-natal
lethality17. Whether or not LATS1/2 has a role in neuronal dif-
ferentiation in mammals is not known. We tested if deficiency in
YAP1 phosphoregulation by LATS1/2 is sufficient to cause
tumour formation by conditionally knocking out Lats1 and Lats2,
in NEX-Cre lineage (Fig. 3a). We found that dual LATS1/2 con-
ditional knockouts (cKOs), but not individual LATS1 cKOs or
LATS2 cKOs, have significantly reduced body weight by P19-P21
compared with control littermates, with an onset of difference at
P15 (Supplementary Fig. 3a, b). Upon inspection of LATS1/2 cKO
mice at P0–P21 age groups, we found that 67% at P5–P7 and
100% at P8–P21 developed tumours whereas no tumours were
found before P5 (Supplementary Fig. 3c). Multiple clonal fore-
brain tumours, originating invariably at the ependymal layer were
found in all LATS1/2 cKOs, but not in controls or individual
LATS1 cKOs or LATS2 cKO at P20 (18/18 dual knockout, 0/3
LATS1 cKO, 0/3 LATS2 cKO, 0/6 controls), indicating redun-
dancy between LATS1 and LATS2. Animals showed multifocal,
discrete tumours indicating their synchronous origin (Fig. 3b).
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Fig. 1 YAP1 is present in ependymal layer and its regulation is critical for brain development. a Coronal view of control P0 mouse brain sections
immunofluorescence stained for YAP1. Arrowhead pointing at strong positive staining in the ependymal layer, scale bars= 1 mm. b–c Higher magnifications
of ependymal layer/ventricular zone in control mice at P0. b Immunostainings with YAP1 and Nestin and c. Immunostainings with YAP1 and Ki67 show
colocalization (arrows point to cells with colocalizations, overlap shown in white colour). Scale bars= 10 µm. d Breeding scheme to generate mice
expressing nlsYAP5SA under the control of NEX-Cre (referred to as nlsYAP5SA). Mice with only one allele of NEX-Cre without the YAP1 transgene were
used as controls. e Sagittal vibratome sections of the whole brain of Control and nlsYAP5SA mice are shown at P14. In nlsYAP5SA mice, ependymal layer is
destructed, multiple tumours are formed across the brain as shown by DAPI stained nuclei and hippocampus is not developed. Arrowheads point at
hippocampus. Scale bar= 1 mm.
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LATS1/2 cKO brains were collected at predetermined time points
(mostly at P20) as permitted by our project licence and were not
assessed by survival (see methods). Based on the severity indica-
tions, we believe the majority of LATS1/2 cKO mice and all
nlsYAP5SA mice were moribund before 2 months of age. YAP1
was expressed in all tumours including the smallest lesions
observed in younger animals. This finding indicates that loss of
LATS1/2 function increases YAP1 activity (Fig. 3c). In LATS1/2
deletion induced tumours, YAP1 was highly expressed in the
cytoplasm of all cells and was enriched in the nucleus in a subset
of cells in tumour, in a mosaic fashion (Fig. 3d, e). Although some
cells expressed high levels of YAP1 in the nucleus, some had less-
intense YAP1 levels in nucleus (Fig. 3d, e). These results indicate
that in LATS1/2 cKO tumours YAP1 nuclear localisation can be
regulated by additional factors, such as actomyosin and Src kinase,
as previously shown49. Furthermore, YAP1-positive tumours in
this early stage of development showed increased nestin expres-
sion and nestin was present in cells expressing nuclear YAP1 as
well as those that had increased YAP1 in cytoplasm (Fig. 3e). In
addition to the periventricular tumours, we observed tumour
formation in the cerebellum (Supplementary Fig. 3d), recapitu-
lating the features of nlsYAP5SA; NEX-Cre mice (Fig. 1e). These
data show that LATS1/2 loss in NEX-Cre expressing neural pre-
cursor cells cause YAP1-expressing tumours that are highly
similar to tumours found in nlsYAP5SA; NEX-Cre mice. Our
finding of much smaller clonal tumour formation in LATS1/2
cKO mice, when compared with nlsYAP5SA; NEX-Cre mice is
likely owing to other regulators of YAP1/TAZ activity, such as Src
and NDR kinases50,51. Therefore, LATS1/2 activity in NPCs is
necessary to control YAP1 activity during development.
Tumours in LATS1/2 conditional knockout mice are YAP1/
TAZ dependent. Although it is generally accepted that YAP1 is
the main functional output of the hippo pathway and that its
dysregulation leads to tumourigenesis, it remains to be tested
whether YAP1 has an essential role in Lats1/2-dependent brain
tumour generation. YAP1 exhibits largely redundant functions
with its close homologue TAZ. Therefore, we used YAP1 f/f; TAZ
f/+ mice50 to assess if YAP1/TAZ are required for tumorigenesis
in LATS1/2 dual knockout mice. For this purpose, we crossed
NEX-Cre; Lats1 f/f; Lats2 f/f mice with YAP1 f/f; TAZ f/+ mice
(Fig. 4a). We found that all LATS1/2 cKO animals where one or
both copies of YAP1 was deleted still exhibited tumours at P20
(n= 3 each), indicating that YAP1 is not the sole downstream
factor regulated by LATS1/2. However, we observed that LATS1/2
cKO animals depleted of both copies of YAP1 exhibit a significant
reduction (p < 0.001, Dunn’s multiple comparisons test) in average
tumour size compared with LATS1/2 cKO animals (Fig. 4b),
indicating that level of YAP expression impacts tumour size.
Further, using a random effects model to account for multiple
tumours being recorded from each animal, we observe significant
evidence of an additive dosage effect, specifically each YAP1 WT
allele lost corresponds to a decrease in estimated tumour volume
of ~0.03mm3 (p= 0.0068). In LATS1/2; YAP1f/f mice, tumours
were negative for YAP1 immunostaining supporting its specificity
(Supplementary Fig. 4a). LATS1/2 cKO YAP1f/+ TAZf/+ mice
have tumours (n= 3). However, tumour formation was sup-
pressed at P20 in LATS1/2 cKO YAP1f/f TAZf/+ mice (n= 3)
(Fig. 4c). These results strongly support that activation of both
YAP1 and TAZ mediate tumour formation in LATS 1/2 cKO mice
(Fig. 4c). We conclude that YAP1 and TAZ are necessary for
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Fig. 2 Uncontrolled YAP1 in NEX-Cre-expressing cells is sufficient for tumour formation at the expense of hippocampal differentiation. a Immunofluorescence
staining of YAP1 in coronal vibratome sections of P0 animals. Neurons in nlsYAP5SA mouse cortex show strong nuclear staining of YAP1. Hippocampus
formation is altered in nlsYAP5SA (arrowheads). Scale bars= 1 mm. b Arrowheads pointing at tumours visible in coronal vibratome sections of a P0
nlsYAP5SA animal. Scale bars= 1 mm. c Immunofluorescence staining in coronal sections of tumours in a nlsYAP5SA mice. Tumours are outlined with
yellow-dashed line. Nestin, Ki67 and MUC1 demonstrate highly intense staining in the tumours while NeuN is absent. Scale bars= 100 µm.
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LATS1/2-dependent tumourigenesis arising from NEX expression
NPCs.
LATS1/2 cKO tumours recapitulate features of human epen-
dymoma. We next investigated the pathological features of the
LATS1/2 cKO tumours. Serial sections of paraffin embedded P20
LATS1/2 cKO mice brains showed periventricular multifocal
tumours in continuity with the ependymal layer (Fig. 5a). His-
tologically, the tumours appeared as moderately cellular lesions
with a compressive margin. They were composed of uniform
spindle or rounded cells with fibrillary or scanty cytoplasm and
slightly hyperchromatic nucleus (Fig. 5b, c). We did not observe
well-formed perivascular pseudo-rosettes. Some cells contained
intracytoplasmic vacuoles (Fig. 5d). Mitoses were absent. The
tissue surrounding these lesions showed reactive astrocytosis and
microglial response. Tumour cells showed nuclear and lesser
extent cytoplasmic YAP1 expression (Fig. 5e), they weakly
expressed MUC1 (EMA) (Fig. 5f) and they were focally positive
for GFAP (Fig. 5g) and cytokeratin 18 (Fig. 5h). Vimentin, nestin,
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Fig. 3 Conditional knockout of LATS1/2 under control of NEX-Cre leads to clonal YAP1-positive tumours. a Breeding scheme to generate LATS1/2
conditional knockout (LATS1/2 cKO) mice and control littermates. b Tumours associated with the ependymal layer are found in LATS1/2 cKO mice at P20
(arrowheads). Multiple clonal tumours can be found in each brain (middle and right images are from the same brain at different coronal planes). Scale
bars= 1 mm. c A coronal section of LATS1/2 cKO brain at P6 shows strong YAP1 immunofluorescence staining in a tumour arising from the ependymal
layer (arrowhead). Scale bars= mm. d–e Confocal images of immunofluorescence stainings in LATS1/2 cKO brains. Scale bars= 10 µm. d YAP1 staining
is increased in the tumour and YAP1 is nuclear in some cells (arrowheads). YAP1 expression does not overlay with GFAP+ cells. e YAP1 and Nestin are
co-expressed in the tumour cells (arrows).
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which are present in radial glia were also expressed in tumours,
whereas neuronal marker NeuN was consistently absent (Sup-
plementary Fig. 5a). Ki67 was expressed in tumours indicating
cell division (Supplementary Fig. 5a). Notably, normal ependyma
in mice also expressed cytokeratin 18 as previously shown52
(Supplementary Fig. 5b). Light microscopic features and immu-
noprofile of the tumours were consistent with ependymoma and
similar to the human counterpart53–55.
To further test the ependymal origin of LATS1/2 cKO tumours,
we performed ultrastructural examination using transmission
electron microscopy (TEM). After identifying the areas of the
tumour mass using Micro-CT by comparing to nuclear 4′,6-
diamidino-2-phenylindole (DAPI) fluorescent image of the brain
(Supplementary Fig. 5c), we studied multiple regions of the
tumour using serial blockface scanning electron microscopy
(Supplementary Fig. 5d) and TEM (Fig. 5i–k, Supplementary
Fig. 5e–f). Numerous microvilli and tight junctions (Fig. 5i–k,
Supplementary Fig. 5f) were observed in different regions of the
tumour. Presence of microvilli and tight junctions confirmed that
YAP1 dysregulation and activation leads to the formation of
ependymal tumours similar to the corresponding tumours seen in
humans.
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Fig. 4 YAP1 and TAZ are necessary for tumour development in LATS1/2 cKO mice. a Breeding scheme to generate a rescue model. Available animals
(Lats1f/f Lats2f/f, YAPf/f TAZf/+ and NEXCre/Cre) were crossed to generate mice with shown genotypes. b Measurements of size of tumours found in
LATS1/2 cKO (n= 16 tumours), Mutant YAPf/+ (n= 15 tumours) and Mutant YAPf/f (n= 11 tumours) from n= 3 mice for each genotype. Colour shade
indicates tumours from the same animal. LATS1/2 cKO tumour volumes compared with those measured in Mutant YAPf/f animals show a significant
difference with padj= 0.0006 (two-sided Dunn’s multiple comparison test). Error bars= SEM. c Coronal vibratome sections of P20 brains stained for
DAPI. No tumour formation identified in Rescue mice. Tumours (arrowheads) can be found in LATS1/2 cKO, Mutant YAPf/f and Mutant YAPf/+ animals.
Scale bars= 1 mm.
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RNA sequencing and proteomics in nlsYAP5SA brain. We
performed total RNA sequencing of the right hemisphere of
nlsYAP5SA mice (NEXCre/+; YAP1nlsYAP5SA/+) and unaffected
littermates (NEX+/+; YAP1nlsYAP5SA/+) (n= 5 for each
genotype) (Fig. 6a). Experiments included three additional non-
littermate C57BL/6 controls, which clustered with the control
animals, but were not included in later analysis (Supplementary
Fig. 6a). First, we ranked all 30,280 identified genes based on their
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Fig. 5 LATS1/2 cKO mouse tumours display histological features of ependymoma. a–d The tumour (arrowhead) appear to arise from the ependymal
layer of the anterior temporal horn of the lateral ventricle at the level of hippocampus (* CA3). a H&E, ×4, scale bar= 500 µm; the lesion has compressive
margin. b H&E, ×10, scale bar= 200 µm and it is composed of fascicles of spindle cells with focal nuclear clustering. c. H&E, ×40, scale bar = 50 µm. A few
tumour cells contain intracytoplasmic, paranuclear vacuoles (arrowheads). d. H&E, ×60, scale bar= 20 µm. Tumour cells demonstrate. e nuclear and
cytoplasmic YAP1 expression (immunoperoxidase, ×20), f weak cytoplasmic MUC1 expression (immunoperoxidase, ×20) and g they are focally positive
for GFAP (immunoperoxidase, ×20) and h cytokeratin 18/CK18 (immunoperoxidase, ×10). Reactive astrocytes surrounding the lesion are also GFAP-
positive (g—immunoperoxidase, ×20). Scale bars= 50 µm. i TEM image (×9900) within the tumour showing multiple ependymal features (Yellow
arrowheads=microvilli, red arrows= tight junctions). Scale bar= 1 µm. j, k. Enlargement of the yellow and red insets in i, respectively. Scale bars=
200 nm. j. High magnification of microvilli and k. a tight junction found in the tumour are shown.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16167-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2380 | https://doi.org/10.1038/s41467-020-16167-y | www.nature.com/naturecommunications 7
differential expression in nlsYAP5SA and control. We then
applied gene enrichment analysis (GSEA) choosing the Kyoto
Encyclopaedia of Genes and Genomes (KEGG) database to
identify gene sets that are overrepresented at both extremes of the
ranked list. Among the top 10 upregulated gene sets in
nlsYAP5SA we found pathways in cancer, cytokine receptor
interaction and focal adhesion, in agreement with active YAP1’s
capacity to induce cancer and a consequent immune response
(Fig. 6b, c). On the other side, Oxidative Phosphorylation gene set
among the most reduced, which may indicate changes in energy
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metabolism tumours (Supplementary Fig. 6b). In a com-
plementary analysis, we analysed the 2035 significantly differen-
tially expressed genes between the two genotypes utilising the
online tool DAVID with KEGG defined gene sets. The sig-
nificantly differentially expressed gene list was generated using
the DESeq2 R package applying the Wald significance test with a
threshold of 0.05 for significance. As expected, one of the most-
enriched gene sets was the hippo signalling pathway in addition
to terms including immune and infection-related genes (Supple-
mentary Fig. 6c). Specifically, in nlsYAP5SA mice numerous
known YAP1 downstream effectors56 were significantly upregu-
lated at mRNA level, including AMOTL2, CTGF, CYR61,
ANKRD1 and AXL (Supplementary Data 1).
Next, we inspected how gene expression signatures in our
nlsYAP5SA mouse models compare with published gene expression
data from human ependymoma subtypes. For this we used a list of
genes that was previously established to be differentially expressed
between YAP1-MAMLD1 fusion and RELA fusion-positive human
ependymoma subtypes, as well as between YAP1-MAMLD1 and
C11orf95-RELA-driven mouse ependymoma models31,57. Of these
354 published unique genes (151 YAP1 associated and 203 RELA-
associated), 350 were present in our transcriptomics data, which we
ranked with respect to fold change in nlsYAP5SA compared with
control mice (Fig. 6d). We found that although RELA fusion-
associated genes were equally represented among increased and
reduced genes in nlsYAP5SA model (Fig. 6d, red), genes that are
specific for YAP1-MAMLD1 fusion-positive ependymoma were
clearly overrepresented among upregulated genes in the nlsYAP5SA
model (Fig. 6d; teal, Supplementary Data 2). When we restricted the
analysis to mRNAs that are significantly changed between control
and nlsYAP5SA mice (89/354 genes were found in our significantly
differentially expressed gene list, matched by gene name) we found
that this pattern was even more striking. In all, 45 out of the 46
(98%) YAP1-MAMLD1 fusion-associated mRNAs were signifi-
cantly increased in our mouse model and only one mRNA was
reduced, in contrast 20 out of 43 (46%) RELA fusion-specific genes
were increased and 23 were reduced in nlsYAP5SA mice
(Supplementary Fig. 6d, Supplementary Data 2). These data show
that the proportion of YAP-associated genes that are increased in
nlsYAP5SA are much higher than RELA-associated genes (p <
0.0001, Chi-squared test), indicating that YAP-MAMLD1 fusion-
associated gene expression signatures are present in nlsYAP5SA
model. The 18 genes with the highest expression changes in
nlsYAP5SA included known YAP1 downstream target genes such
as Ankrd1, Cyr61 and Ctgf (Fig. 6e)56. Interestingly, cytokeratin 18,
a marker expressed in the ependymal layer and in our LATS1/2
cKO tumours was among the top 10 increased genes in nlsYAP5SA
mice (Fig. 6e). These data support that nlsYAP5SA expression in
NPCs lead to a gene expression profile that resembles human
ependymomas with YAP1-MAMLD1 fusion. We attempted to
perform a principle component analysis between multiple types of
paediatric brain tumour gene expression58 and our nlsYAP5SA
mice-sequencing results. We did not observe a strong clustering of
the individual patient tumour types (Supplementary Fig. 6e), thus
were not able to compare nlsYAP5SA tumours either, leading this
analysis to be inconclusive. Substantial technical caveats were
associated with comparing microarray data set with our next-
generation sequencing data set (see methods).
To investigate whether the changes we observed in mRNA
expression are translated to protein level changes, we took a mass
spectrometry approach. The left hemispheres of the nlsYAP5SA
and control animals (n= 5, each) that were used in the
transcriptomic screen were labelled with a TMT (Tandem Mass
Tag) 10-plex reagent to enable relative proteome quantification.
We identified a total of 6643 proteins, 21.3% of the identified
mRNAs were represented at the protein level and we find an
overlap of 85 genes and proteins that were significantly increased
in both data sets in nlsYAP5SA compared with control when
matched by gene name (Fig. 6f). The principal component
analysis of the proteomics data shows two distinct clusters clearly
separating the different genotypes (Supplementary Fig. 6f). We
observed a correlation between the transcript (Stat value) and
protein (Welch difference) levels with a Pearson’s correlation
coefficient of 0.5 (Fig. 6g, Supplementary Data 3). Next, we
calculated categorical enrichment in two dimensions as described
previously59. Gene ontology (Biological Processes, Molecular
Function and Cellular Compartment) and KEGG were annotated
both on the transcript and the protein level. These data revealed a
good correlation between the transcriptome and proteome data
on the categorical level (Supplementary Fig. 6g, Pearson’s r=
0.844 correlating 2D enrichment scores). GFAP, vimentin and
ANXA1 were specific examples of genes that were increased at
mRNA as well as protein levels in nlsYAP5SA brains (Fig. 6g) and
these were previously associated with ependymoma60.
To investigate if increased proteins can be associated with a
particular cell type we analysed our proteomics data separately by
overlaying it with an existing data set of full proteomics performed
on isolated CNS cells61. We show that in tumour bearing mice
there is an increase in microglia and astrocyte associated proteins
(Fig. 6h, i, Supplementary Fig. 6h, i; Supplementary Data 4),
Fig. 6 Transcriptome and proteome analysis of nlsYAP5SA mice exhibit further parallels to human ependymoma. a–e Gene expression analysis for
nlsYAP5SA versus control. Five animals per genotype (control=NEX+/+ YAP1nlsYAP5SA/+; nlsYAP5SA=NEXCre/+ YAP1nlsYAP5SA/+) were analysed
utilising the Illumina HiSeq 4000. a Heat map of all significantly differently expressed genes (2035 genes) between control and nlsYAP5SA animals. Rows
represent genes and columns show individual animals. Legend indicates per gene median centred fold change. b Gene enrichment analysis (GSEA) of
complete gene list (30,280 detected genes) from RNA sequencing (RNASeq) with gene sets derived from the KEGG pathway database. The top 10
annotated pathways with the highest normalised enrichment score (NES) are shown with number of genes in the data set linked to the indicated pathway
(Size). c GSEA of KEGG annotation “Pathways in Cancer” with highest NES in analysis. d Gene list of YAP1 and RELA association (see methods) was used
to assign specificity to detected genes in our expression data from nlsYAP5SA screen (350 genes of the 354 in reference list are present in our data set).
Log2 fold change of control vs. nlsYAP5SA are ranked from highest to lowest. Teal and red colours are used to denote YAP-specific and RELA-specific
genes, respectively. e The 10 highest ranked genes with assigned specificity all of these are associated with YAP1. f Venn diagrams illustrating numbers of
identified genes in Transcriptome (RNAseq, blue) and proteome quantified by liquid chromatography mass spectrometry (LC-MS) (red). Left: all genes,
right: significantly upregulated genes in nlsYAP5SA. g Density scatter plot of 6439 genes present in both proteome and transcriptome plotted by their
expression difference between control and nlsYAP5SA (Welch difference is used for proteomics and stat value is used for transcriptomics). Data sets show
a correlation coefficient of 0.5. Each point represents one gene. h Volcano plot of difference in protein levels between control and nlsYAP5SA cohort. Each
point represents one protein. The x axis shows log2 transformed fold change and the y axis shows significance by –log10 transformed p value obtained by
two-sided Welch t test. A gene is called significantly and differentially expressed if its FDR is <0.05 and s0 > 0.1, which is indicated by the black line.
Proteins associated with astrocytes (magenta) and microglia (green) are displayed. Cell type association was generated by integrating previously published
data (see methods). i Area shown in h, enlarged to display and name significantly upregulated proteins in nlsYAP5SA brains.
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indicating a microglial response to the tumour. In addition,
complement cascade proteins such as C1qa, C1qb, C1qc and C4b
are highly upregulated in agreement with the GSEA pointing
towards immune response components (Fig. 6b, Supplementary
Fig. 6c). Interestingly, the known YAP1 target CTGF was
upregulated in mRNA level but was unchanged at protein level
(Fig. 6g), which was further confirmed with western blot (Fig. 7a),
suggesting additional posttranscriptional control. Overall, we
observed good correlation of our proteomics and transcriptomics
analysis, which together strongly support that nlsYAP5S brain
tumours resemble YAP1-fusion-positive ependymoma and activate
known YAP target genes.
YAP1 effectors are highly expressed in LATS1/2 cKO tumours.
First, we confirmed that Vimentin, GFAP and HOPX were highly
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increased in nlsYAP5SA brains, where FLAG-tagged YAP1 over-
expression can be observed (Fig. 7a). Next, we wanted to know if
genes and proteins upregulated in nlsYAP5SA mice were also
upregulated in LATS1/2 knockout mouse tumours. Using immu-
nofluorescence, we found that YAP1 downstream effectors iden-
tified in mRNA analysis, ANKRD1, AMOTL2 and AXL were
increased in LATS1/2 cKO tumours (Fig. 7b). ANKRD1 was
abundant in the tumour centre, while AMOTL2 and AXL were
higher at periphery, where C3-positive microglia were also
observed (Supplementary Fig. 7a). These results suggest that
canonical YAP1 signalling effectors are relevant to tumorigenesis of
ependymoma-like tumours in both of our mouse models.
In addition to YAP1, Homeodomain-only protein (HOPX) was
the only transcription cofactor that was significantly increased in
mRNA sequencing and proteomics analysis (Fig. 6g–i). HOPX is
a transcriptional regulator expressed in many tissues including
neuronal stem cells with astrocytic fate62,63. HOPX was present in
nucleus as well as cytoplasm, especially at high levels in wild-type
mouse cerebellum and dentate gyrus (Supplementary Fig. 7b).
HOPX protein was increased in nlsYAP5SA mice (Supplementary
Fig. 7c) and in LATS1/2 cKO tumours (Fig. 7c). HOPX co-
localised with cells expressing nuclear YAP1 in LATS1/2 cKO
tumours (Fig. 7d). These results indicate that HOPX expression is
robustly induced in tumour cells with YAP/TAZ activity.
HOPX is expressed in human YAP1-fusion ependymoma. We
next used our proteomics data to predict potential YAP1-fusion
ependymoma-specific markers, reasoning that increased protein
levels may lead to easier detection with immunostainings. We
focused on ANKRD1 and HOPX because upregulated astrocytic
and microglial proteins were unlikely to be subtype specific. We
used sections of human ependymomas with confirmed YAP1-
MAMLD1 and C11orf95-Rela fusions (n= 3 patients each).
Nuclear YAP1 expression was present in YAP1-MAMLD1
(Fig. 7e), as previously observed64, nuclear p65 expression was
only observed in C11orf95-RELA-fused ependymoma in keeping
with current literature64,65 (Supplementary Fig. 7d). Ankrd1
antibody did not yield specific staining IHC. Interestingly, we
found that HOPX was expressed in the three YAP1-MAMLD1-
induced human ependymoma, while largely absent in three
C11orf95-RELA-induced ependymoma (Fig. 7e, Supplementary
Fig. 7d). HOPX has been reported to be absent or suppressed in
malignancies63,66 and has been identified as a significant enhancer
in YAP1-fused ependymomas67. It is possible to speculate that
HOPX expression may impact on the more favourable outcomes
of YAP1-fusion ependymoma32. These first results will be fol-
lowed up by larger cohorts in future studies.
Discussion
Our study demonstrates that control of YAP1/TAZ activity in
neuronal precursor cells at VZ by LATS1/2 kinases is critical for
limiting their proliferation. Upon nlsYAP5SA expression, hip-
pocampal neuron differentiation is severely affected. These results
are in line with the findings that NF2, a positive regulator of
hippo signalling, also alters hippocampal formation by limiting
progenitor numbers and enabling hippocampal neuron differ-
entiation; effects mediated by YAP168,69. Our LATS1/2 cKO
mouse model data indicate that LATS kinases play a role in
suppressing YAP1 activity in progenitors, thus establishing a
requirement for the canonical LATS-YAP1 signalling pathway in
limiting progenitor proliferation.
Mouse models of ependymoma are important for under-
standing the pathogenesis of this tumour and its subtypes and
developing therapeutic interventions. Alongside patient-derived
xenografts70,71, mouse models of ependymoma that mimic genetic
causes in cells of origin are invaluable for studying tumour
development57,72,73. For example, isolated cerebral embryonic
neural stem cells from Ink4a/Arf-deleted mice, a genetic aberra-
tion previously observed in human ependymoma33 were trans-
formed by an Ephb2-expressing virus72. This mouse model,
mEPEphb2re, was used in high-throughput screens, which identi-
fied 5-fluoroucil as an effective treatment74, a hypothesis that is
being tested clinically75. More recently, a mouse model, RELAFUS1
was generated by transducing nestin expressing mouse stem cells
with a c11ORF95-RELA fusion protein73. In both mouse models,
upon engrafting, tumours with profound similarities to ependy-
moma were formed72,73. Similar to other ependymoma mouse
models57,72, in LATS1/2 cKOs we did not observe rosettes or well-
formed pseudo-rosettes, which are commonly observed in human
ependymomas and are also present in the mEPEphb2 model71. We
speculate that formation of these structures may depend on
tumour size and species.
The tumours generated by increased YAP/TAZ activity in our
nlsYAP5SA and LATS1/2 cKO mouse models are located in the
periventricular region, similarly to ependymoma with YAP1-
MAMLD1 fusion in humans, which consistently show a peri-
ventricular location, with or without an intraventricular compo-
nent32, in contrast with RELA-fused ependymoma, which tend to
occur more often in cortical-centred location64. A recent pub-
lication showed that YAP1-MAMLD1 fusion in nestin-positive
neural stem cells induce ependymoma-like tumours in mice57. In
this model, MAMLD1 was necessary for the nuclear localisation
of YAP1 and confers specific properties to YAP1-dependent gene
regulation57. Our nlsYAP5SA and LATS1/2 cKO mouse models
indicate the notion that YAP/TAZ activity alone is sufficient for
ependymoma-like tumour formation. This result supports that
the main function of fusion proteins such as MAMLD1 may be
nuclear localisation and/or activation of YAP/TAZ. Importantly,
by using transcriptomics analysis, we found that nlsYAP5SA
brains have similar gene expression patterns to YAP1-MAMLD1
fused ependymoma and YAP1-MAMLD1 fusion induced mouse
model57. We were not able to demonstrate a clustering of our
Fig. 7 Validation of markers identified in our proteomics and transcriptomics screen in mouse and human models of ependymoma. aWestern blots and
quantification of proteins levels comparing control and nlsYAP5SA animals (control=NEX+/+ YAP1nlsYAP5SA/+; nlsYAP5SA=NEXCre/+ YAP1nlsYAP5SA/+)
(n= 3 mice, each). Significant increase in YAP1 (p= 0.0042), Vimentin (p= 0.0017), GFAP (p < 0.0001) and HOPX (p= 0.0002) are observed in
nlsYAP5SA (two-tailed unpaired t tests). No significant difference in protein level was observed for TAZ nor CTGF. Error bars= SEM. b Immunofluore-
scence stainings for selected YAP1 downstream genes in LATS1/2 cKO tumours at P20. Strong staining of ANKRD1, AMOTL2 and AXL are observed in the
tumour. ANKRD1 was uniformly expressed in throughout all tumour cells, AMOTL2 and AXL exhibited higher levels in tumour near its border. Scale bar=
100 μm. c Immunofluorescence of HOPX and YAP1 in a LATS1/2 cKO tumour at P20, showing higher staining at tumour edge, HOPX co-localises with
YAP1 in this area (white shows colocalisation, Scale bar= 100 μm). d A subset of HOPX expressing cells have clear, nuclear YAP1 staining, example cell
shown from a different LATS1/2 cKO tumour (Scale bar= 10 μm). e Two YAP1-MAMLD1-fused ependymoma characterised by uniform cells forming
pseudo-rosettes in a fibrillary background (H&E, scale bar= 100 μm (Patient 1), 200 μm (Patient 2)); tumour cells show YAP1 nuclear expression
(immunoperoxidase, scale bar= 50 μm); there is cytoplasmic and nuclear expression of HOPX (immunoperoxidase, scale bar= 100 μm), whereas p65 is
negative in tumour cells (immunoperoxidase, scale bar= 100 μm).
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nlsYAP5SA gene expression data with ependymoma, when using
a data set with multiple paediatric brain tumour microarray
analysis58. To establish the relationship of nlsYAP5SA mouse
model to paediatric tumours in general and strengthen it as a
preclinical model, it would be necessary to compare our mRNA
sequencing data set with next-generation sequencing data sets of
paediatric brain tumours, including YAP1-fusion ependymoma.
Using genetic rescues by deleting YAP1 and TAZ from the same
cells with LATS1/2 deletion, we demonstrated that either of these
paralogs can lead to tumour formation. Our results show that
increased YAP/TAZ activity is sufficient to ependymoma-like
tumours in mice.
It was advantageous in this study to combine transcriptomics
with proteomics, as some mRNA changes may not be reflected in
protein levels. Our proteomics screen was able to detect ~21% of
genes detected in our RNA sequencing screen, with the highest
proteomic hits indicating high protein abundance and therefore
potential use as histological markers for diagnosis and therein
prognosis. With this reasoning we tested HOPX in IHC and
showed high level of expression in tumours with YAP1-MAMLD1
fusion. Future studies in large cohorts of ependymoma subtypes
would be needed to assess subtype-specificity of this marker.
Nevertheless, these data support the use of nlsYAP5SA and
LATS1/2 cKO mice as ependymoma models.
Our proteomics screen showed a striking increase in microglia-
associated proteins, such as the ANXA1 and complement factors.
Genomics signatures from whole tissues would inevitably contain
signatures of all cellular types. High-throughput tissue staining
would be needed to clarify cellular subtypes in tumours. In our
LATS1/2 cKO mouse model, although some of the tumour mar-
kers were highly present in the centre of the tumour mass, e.g.,
ANKRD1, Vimentin, CK18, nestin and Ki67, some were localised
towards the edges of the tumour, e.g., HOPX, AMOTL2, AXL and
microglial marker C3. For the latter category, further studies
would be needed to distinguish between a cell autonomous effects
of YAP1 expression in Cre recombined cells from an effect of
YAP1-induced tumours on the surrounding wild-type cells.
Our results show that nlsYAP5SA and LATS1/2 cKO mouse
models are similar to ependymoma in general, in terms of histol-
ogy, immunoprofile and ultrastructural features. Specifically,
nlsYAP5SA mouse tumours highly resemble YAP1-fusion epen-
dymoma in gene expression. Our study suggests that nlsYAP5SA
and LATS1/2 cKO mice are valuable models of YAP1-fusion
ependymoma for biological and preclinical research. Small tumour
sizes, early lethality and lack of pseudo-rosettes may have limita-
tions. Complementary models, such as xenografts, could be used in
conjunction with genetically defined mouse ependymoma models,
to reach a more comprehensive understanding of ependymoma.
Methods
Human tissue and staining. Tissue of six patients were used in this study. Written
consent was given by the patient (one adult RELA tumour) or by legal repre-
sentatives (five children, three YAP and two RELA ependymoma). All tumours at
diagnosis without any previous treatments such as chemotherapy nor radiotherapy.
For IHC tissue analysis of YAP1, HOPX and RELA expression, the patient
tissues were deparaffinised and subject to Heat-Mediated Antigen Retrieval (pH6
Citric Buffer, microwave 23 min). The slides were incubated with YAP1 (1:400, Cell
Signalling #14074), HOPX (1:250, Proteintech #11419-1-AP), NF-kB p65 (1:800,
Cell Signalling #8242) in signal stain diluent overnight at 4 °C and 45 min in
secondary antibody. Diaminobenzidine was utilised as the chromogen and the
sections were counterstained with haematoxylin. Images were acquired with a Leica
DM2500 LED.
Animals. Maintenance and handling of animals were performed under regulations
of the Animal (Scientific procedures) Act 1986 of the United Kingdom and
approved by institutional ethical reviews. Mice were group housed and maintained
on a 12 hr light/dark cycle, with food and water provided ad libitum. None of the
experimental mice were immune compromised. Both male and female mice were
used and randomly allocated to experimental groups according to genotypes.
LATS1/2 cKO and nlsYAP5SA mice were closely monitored and weighed regularly.
The majority of LATS1/2 cKO mice were collected at <3 weeks of age. In accor-
dance to our project license, a subset of LATS1/2 cKO animals were aged up to
2 months of age, provided they did not exceed 10% weight loss criteria (~50% were
collected before reaching 1 month of age to prevent reaching this end point) and
nlsYAP5SA mice were aged only up to 2 weeks owing to higher severity.
Nex-Cre (Neurod6tm1(cre)Kan, MGI:2668659) was a generous gift from Dr.
Klaus Nave. Lats1f/f Lats2f/f Lats1(tm1.1Jfm) MGI:5568586 and Lats2(tm1.1Jfm)
MGI:5568589 mouse was kindly provided by Dr. R. Johnston (University of Texas
MD Anderson Cancer Center, USA). Ai14 (Gt(ROSA)26Sortm14(CAG-tdtomato)Hze)
was purchased from Jackson Laboratories (Stock Number:007908). YAP1f/f
(Yap1tm1c(KOMP)Mbp, MGI:5603606), TAZf/f (Wwtr1tm1c(EUCOMM)Wtsi, MGI:
5603602) mice were from Barry Thompson’s laboratory and nlsYAP5SA mice
were described previously45.
Tissue preparation, immunofluorescence and imaging. For brain tissue section
staining, P0 mice were decapitated and the brain fixed in 4% ice-cold paraf-
ormaldehyde (PFA) in PBS for 2 days at 4 °C. Older animals were transcardial
perfused with 4% ice-cold PFA under terminal anaesthesia. Brains were dissected
out and post-fixed in 4% PFA overnight at 4 °C. For immunofluorescence, coronal
or sagittal sections were prepared with a vibratome at 50 µm. The sections were
blocked with 10% serum and 0.2% Triton-X in PBS and incubated with primary
antibody in blocking solution overnight at 4 °C. Used antibodies include AMOTL2
(1:100, GeneTex # CTX120712), ANKRD1 (1:100, Proteintech #11427-1-AP), AXL
(1:100, R&D Systems #AF854), C3 (1:100, Abcam #ab11862), Cre (1:500, Covance
#PRB-106P), Ctip2 (1:500, Abcam #ab18465), GFAP (mouse 1:500, Sigma #G6171
and chicken 1:1000, Abcam #ab134436), HOPX (1:100, Proteintech #11419-1-AP),
Ki67 (1:100/1:300, BD #550609), MUC1 (1:500, Abcam #ab45167), Nestin (1:100,
Millipore #MAB353), NeuN (1:100, Millipore #MAB377) and YAP1 (rabbit 1:100,
CST #14074 and mouse 1:100, Santa Cruz Biotechnology #sc-101199). Sections
were incubated with the appropriate Alexa fluor 488-, 546- or 647-conjugated
secondary antibodies (1:500; ThermoFisher) for 2 hr at room temperature. Nuclei
were stained using DAPI. Sections were mounted on slides with Fluoromount.
Images were acquired with Olympus IX83 or a Leica MPSP5 Upright Confocal as
indicated in the figure legends.
Histology and IHC. Brains subject to histological analysis were dehydrated and
embedded in paraffin after completion of 4% PFA fixation. The tissues were sec-
tioned (4 µm) and sections were prepared for H&E or IHC. Unless stated otherwise
the heat induced antigen retrieval (citrate buffer pH= 6, 23 min microwave) has
been applied and primaries were incubated for 1 hr at RT. The following antibodies
were used for IHC; CK18 (1:3000, ThermoFisher #PA5-14263; Tris-EDTA pH9),
GFAP (1:750, DAKO #z0334), HOPX (1:250, Proteintech #11419-1-AP), Ki67
(1:350, Abcam #ab16667), MUC1 (1:500, Abcam #ab15481), Nestin (1:600, BD
Biosciences #611659), Rela/NF-kB p65 (1:800, Cell Signalling #8242), (NeuN
(1:600, Chemicon #MAB377), Vimentin (1:600, Abcam #ab92547), YAP1 (1:400,
CST #14074; in signal stain (from CST) overnight at 4 °C). Slices were imaged
using the Olympus VS120 Slide Scanner and/or the Leica DM2500 LED.
Electron microscopy. For serial blockface scanning electron microscopy (SBF
SEM) and TEM, mouse brains were perfused fixed in 2% PFA, 2.5% GA in 0.1 M
PB pH 7.4 and post-fixed for at least 4–5 hours in 2% PFA in 0.1 M PB pH 7.4 at
4 °C. The brains were then sectioned using a Leica VT1000 S vibrating blade
microtome (Leica). In all, 50 and 100 µm sections were collected and stored in
0.1 M PB. The 50 µm sections were then stained with DAPI and imaged as pre-
viously to identify the locations of the tumours. The consecutive 100 µm sections
were then transferred to polypropylene 24-well plates (Caplugs Evergreen, Buffalo,
USA) and processed using a Pelco BioWave Pro+ microwave (Ted Pella Inc,
Redding, USA) and following a protocol adapted from the National Centre for
Microscopy and Imaging Research protocol (Latest version available: https://ncmir.
ucsd.edu/sbem-protocol). Each step was performed in the Biowave, except for the
PB and water wash steps, which consisted of two washes on the bench followed by
two washes in the Biowave without vacuum at 250W for 40 s. All the chemical
incubations were performed in the Biowave for 14 min under vacuum in 2 min
steps alternating with/without 100W power. The SteadyTemp plate was set to
21 °C unless otherwise stated. In brief, the samples were fixed again in 2.5% glu-
taraldehyde (TAAB)/4% formaldehyde in 0.1 M PB. The cells were then stained
with 2% osmium tetroxide (TAAB)/1.5% potassium ferricyanide (Sigma), incu-
bated in 1% thiocarbohydrazide (Sigma) with SteadyTemp plate set to 40 °C, and
further stained with 2% osmium tetroxide in ddH2O. The cells were then incubated
in 1% aqueous uranyl acetate (Agar Scientific, Stansted, UK) with SteadyTemp
plate set to 40 °C, and then washed in dH2O with SteadyTemp set to 40 °C.
Samples were then stained with Walton’s lead aspartate with SteadyTemp set to
50 °C, and dehydrated in a graded ethanol series (20%, 50%, 70%, 90% and 100%,
twice each), followed by three dry acetone washes at 250W for 40 s without
vacuum. Exchange into Durcupan ACM resin (Sigma) was performed in 25%, 50%
and 75% resin in acetone, followed by 4 pure Durcupan steps, at 250W for 3 min,
with vacuum cycling (on/off at 30 sec intervals), before embedding at 60 °C for
48 h. Blocks were then mounted for micro-computed tomography (micro-CT)) on
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a cylindrical specimen holder with Devcon S-210 epoxy glue. The mounting was
done with the longitudinal axis of the brain section oriented vertically. Tomo-
graphic imaging was conducted in an Xradia Versa 510 (Carl Zeiss Ltd, Cambridge,
UK). A low resolution scan was captured at xkV/xW, with x projections and a pixel
size of x. The region of interest was identified using 3DXMViewer software (Zeiss)
and co-ordinates located for positioning in the Xradia Versa 510. A high-resolution
scan was captured at xkV/xW, with x projections and a pixel size of x. The data
were exported as tiff, to be visualised in 3D in ClearVolume, a plug-in of the FIJI
framework76. The samples were then trimmed to a small trapezoid, excised from
the resin block, and attached to a SBF SEM specimen holder using conductive
epoxy resin (Circuitworks CW2400). Prior to commencement of a SBF SEM
imaging run, the samples were coated with a 2 nm layer of platinum to further
enhance conductivity.
SBF SEM data were collected using a 3View2XP (Gatan Inc., Pleasanton, CA)
attached to a Sigma VP SEM (Carl Zeiss Ltd). Inverted backscattered electron
images were acquired through the entire extent of the region of interest. For each
50 nm slice, a low resolution overview image (horizontal frame width 800 µm for
02/384 µm for 03; pixel size of 78 nm for 02/48 nm for 03; using a 2 µs dwell time)
and several high-resolution images of the different regions of interest (horizontal
frame width 170 µm for 02/183 µm for 03; pixel size of 8.3 nm for 02/11.4 nm for
03, using a 2 µs dwell time) were acquired. The SEM was operated in variable
pressure mode at 5 Pa. The 30 µm aperture was used, at an accelerating voltage of
2.5 kV for 03, 2 kV for 02. In total, 130 (for 02) and 400 (for 03) slices were
necessary to get enough 3D information for an entire tumour. As data were
collected in variable pressure mode, only minor adjustments in image alignment
were needed. All the images were converted as tiff in Digital Micrograph (Gatan
Inc.), and the tiff stacks were automatically aligned using TrakEM2, a plug-in of the
FIJI framework77.
After SBF SEM, the samples were serial sectioned using a UC7 ultramicrotome
(Leica Microsystems, Vienna, Austria) and 70 nm sections were picked up on
Formvar-coated 2 mm slot copper grids (Gilder Grids Ltd., Grantham, UK). The
first sections were viewed using a 120 kV Tecnai G2 Spirit transmission electron
microscope (FEI Company, Eindhoven, Netherlands) and images were captured
using an Orius CCD camera (Gatan Inc.).
Tissue collection from mice. For RNA sequencing and mass spectrometry control
and nlsYAP5SA littermates from two matings were collected at the age of P11 (five
animals per genotype). In additio, three age-matched C57BL/6 animals where
collected. The pups were killed by cervical dislocation, decapitated and the brain
dissected out of the skull. Olfactory bulbs and cerebellum were split off and the
hemispheres were separated. Although the right hemisphere was put into RNAlater
(Qiagen, #76104), the left hemisphere was snap frozen in liquid nitrogen.
For western blotting, control and nlsYAP5SA were collected at the age of P11
(three animals per genotype). The pups were killed by cervical dislocation,
decapitated and the brain dissected out of the skull. As before the olfactory bulbs
and cerebellum were split off and the hemispheres were separated, flash freezing
the right hemisphere in liquid nitrogen.
RNA extraction and sequencing. RNA of tissue stabilised in RNAlater was
extracted using the RNeasy Mini Kit (Qiagen #74104) according to manufacturerʼs
protocol. The samples were quantified via GloMax (Promega) and RNA quality
evaluated using an RNA ScreenTape on the Agilent TapeStation. All RNA samples
had RIN scores above 7. The libraries were prepared with the KAPA mRNA
HyperPrep kit (Roche), normalising samples to 500 ng RNA input and prepared
these into Illumina compatible libraries according to the kit manufacturer’s
instructions. The libraries were normalised and pooled for sequencing. Sequencing
was carried out on the Illumina HiSeq 4000, where the pool was mirrored across
2.5 lanes—yielding an average of 27 million reads per sample (±million reads).
Sample QC, library preparation and sequencing were carried out with the advanced
sequencing facility at the Francis Crick Institute.
RNA sequencing data analysis. Raw fastq files were adapter trimmed using
CutAdapt 1.578 and these trimmed reads were mapped to GRCm38 release 86 with
associated ensemble transcript definitions using STAR 2.5.2a78 wrapped by the R
package RSEM 1.3.079, which was used to calculate estimated read counts per gene.
Where necessary, bam files were merged using samtools 1.8.80. Estimated counts
were normalised and differentially expressed genes were called between genotype
group using the R package DESeq2 1.12.3.81. Genes with an adjusted p value ≤ 0.05
were said to be differentially expressed. Heatmaps were generated using the R
package pheatmap 1.0.8 https://CRAN.R-project.org/package=pheatmapall ana-
lyses were performed using R 3.3.1 (R Core Team “R: A Language and Environ-
ment for Statistical Computing” https://www.R-project.org/). GSEA of complete
pre ranked gene list was done using GSEA 4.0.182 set to classic enrichment statistics
utilising the c2.cp.kegg.v7.0.symbols.gmt gene matrix containing 186 gene sets.
Number of permutations set to 1000, classic enrichment statistic with 15 and
500 set as minimum and maximum, respectively, for set inclusion.
Significantly differentially expressed gene list was uploaded to DAVID 6.883,84
with 44.8% (887) found annotated in KEGG Pathway.
To investigate the resemblance of nlsYAP5SA mouse model to human
ependymoma subtypes, we utilised previously reported microarray data on
differentially expressed genes between human ST-EPN-YAP1 and ST-EPN-RELA
subtypes, which were also present and differentially expressed in YAP1-MAMLD1
induced and C11orf95-RELA induced mouse models of ependymoma31,57. The
summarised synthesis of these subtype-associated, differentially expressed genes
listed in Supplementary Data 6 from ref. 57 was compared with our complete gene
list as well as our significantly differentially expressed gene list. Log2 fold change of
our data set was plotted and the identified of specification was taken from the other
data set using R 3.5.1.
For comparison of the nlsYAP5SA gene expression profile with a previously
published human peadiatric brain tumours data set containing; ependymoma,
glioblastoma, medulloblastoma and pilocytic astrocytoma58. Adjustments made
prior to the comparative analysis: the human Affymetrix microarray report 21,050
probes of which 10,347 (49.2%) have a corresponding Ensemble identifier using the
latest version of the Bioconductor annotation (hgu113aENSEMBL2PROBE). Of
these, 5771 (27.4%) are assigned a gene symbol with an annotated mouse
homologue with a well-defined Ensemble identifier. Almost all of these 5750 are
included in the annotation that we use for the RNA-sequencing analysis. In all, 68
of these had duplicates leaving a total of 5682 RNA-sequencing probes from the
original 21,050 gene probes of the Affymetrix microarray. In total, 5682 gene
expression data (27% of initial Affymetrix probes) were compared with our
sequencing results from Illumina. Normalisation was performed gene-wise: each
data set was individually normalised by median centering and scaling by the
standard deviation for each gene. These scaled data sets were then merged and the
same median centering and standard deviation scaling applied, per gene, to this
merged data set. The heat map was generated with the R package pheatmap in R
3.3.1 (details see above). Substantial reduction of the data set and normalisation
protocols described above constitute considerable caveats for this experiment.
Mass spectrometry and data processing. Liquid chromatography‐tandem mass
spectrometry (LC‐MS/MS) was used to analyse differences in protein expression
in P11 nlsYAP5SA compared with control animals (n= 5 each). The left hemi-
sphere of each animal was taken and lysed in lysis buffer containing 8 M Urea,
50 mM HEPES pH8.2, 10 mM Glycerol 2-phosphate, 50 mM sodium fluoride,
5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM sodium vanadate, 1 mM
dithiothreitol (DTT), 1× Protease Inhibitor Cocktail (Roche), 1× Phosphateae
inhibitor Cocktail, 1 µM okadaic acid and incubated for 30 minutes on ice. Protein
concentration was determined with BCA protein assay according to manufacture
instructions. 100 µg per samples was reduced with DTT, alkylated with IAA,
quenched with DTT and digested with rLysC (Lysyl Endopeptidase, Mass Spec-
trometry Grade (Lys-C), 21-05063, Lot#CAR2347) and Trypsin (Pierce Trypsin
Protease, MS Grade, 90058, Lot#TK276718). After acidification with tri-
fluoroacetic acid (TFA) the samples were desalted on C18 MacroSpin columns
(Nest Group) followed by freeze drying them in liquid nitrogen prior to drying
them on the speed vac. Subsequently the samples were labelled with a TMT
10-plex hit (ThermoFisher, 90110, Lot#TJ268160) according to manufacturer
protocol. TMT labelling efficiency was confirmed (>99%) and mixing check was
performed prior to quenching the labelling reaction. The samples were combined,
partially dried and then cleaned on a C18 SepPak and aliquoted. Subsequently
one-tenth of the sample was resolubilised and fractionated into eight fractions
utilising the Pierce High pH Reversed-Phase Peptide Fractionation Kit (Ther-
moFisher #84868). All samples were dried and resolubilised in 0.1% TFA prior to
LC-MS/MS analysis. Peptides were separated on a 50 cm, 75 µm I.D. Pepmap
column over a 180 min gradient and eluted directly into the mass spectrometer
(Orbitrap Fusion Lumos ETD) with HCD MS2 fragmentation and in a second
injection (7 µl each) analysed in MS3. Xcalibur software was used to control the
data acquisition. The instrument was run in data-dependent acquisition mode
with the most abundant peptides selected for MS/MS by HCD fragmentation.
MaxQuant v1.6.6 was used to process the raw data acquired with a reporter ion
quantification method. Adjusted reporter ion isotopic distributions according to
the TMT Lot number. Protein database searching was done by Andromeda search
engine using the Uniprot KB database of mus musculus sequences (dated 08 Jan
2016). The protein group table was uploaded into Perseus 1.4.0.2 for subsequent
statistical analysis and data visualisation. A two-sided Welch t test with threshold
set to FDR= 0.05 and s0= 0.1 was used to display significance.
To investigate association of proteins to particular cell types the data were
merged with existing data sets from61. From this publication, Supplementary
Data 15 were used to identify protein association to isolated cell types and
Supplementary Data 8 were used to include data from cultured cell types. The data
sets were partially merged (by matching gene name, integrating the log2 fold
expression columns per cell type of the other data set into ours) and association to
particular isolated CNS cell type was defined by expression value being a minimum
of three in one of the four isolated cell types (astrocytes, microglia, neurons and
oligodendrocytes) and with a value of at least double in one compared with any of
the other cell types.
Merging transcriptome and proteome data. The total RNA and protein lists
were merged by gene name and plotted using the stat and Welch difference values
respectively. Annotation was done in Perseus 1.4.0.2 using annotation sets KEGG,
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Gene Ontology Cellular Compartment, Molecular Function and Biological Process.
2D annotation of the proteome and transcriptome was done using Benjamini-
Hochberg FDR as truncation and a threshold value of 0.02.
Western blots. Flash frozen Mouse brains were homogenised by sonication in
sample buffer containing 0.2 M DTT. Lysates were centrifuged at 13,000 g for
15 minutes and supernatants denatured at 95 C for 10 minutes. Equal amount of
protein from the brain lysates were ran on a NuPAGE 4–12% Bis-Tris poly-
acrylamide gels (Invitrogen) and then transferred to a polyvinylidene difluoride
membrane (Millipore). After blocking in 5% non-fat milk in TBST for 60 minutes,
the membrane was incubated with the primary antibodies overnight at 4 °C. The
following antibodies were used; CTGF (1:1000, Abcam, #ab6992); CYR61 (1:1000,
Abcam, #ab24448); GAPDH (1:5000, Abcam, #ab8245); GFAP (1:1000, Sigma-
Aldrich, #G6171); HOPX (1:1000, ProteinTech, #11419-1-AP); TAZ (1:1000,
Abcam, #ab84927); Vimentin (1:5000, Abcam, #ab92547) and YAP1 (1:2000, Cell
Signalling, #14074). Subsequently, membrane were incubated with the horseradish
peroxidase-conjugated (HRP) secondary antibody for 60 minutes—HRP-con-
jugated mouse (1:10,000; Jackson #715-035-151) and HRP-conjugated rabbit (1:
10,000; Jackson #711-035-152). Finally, the membrane was developed with ECL
system (Pierce) and visualised by a chemiluminescence detection system (Amer-
sham WB System). Western blot analysis was performed using ImageJ software
(version 1.52r).
Tumour measurements. Three animals of LATS1/2 cKO, Mutantf/+, Mutantf/f and
rescue were subject to detailed tumour size analysis. The brains were sectioned
coronal using the vibratome with 50 µm depth. Every second section was stained
with a tumour marker (Vimentin, YAP1 or GFAP) to aid tumour identification and
DAPI. All sections were evaluated and imaged using the Olympus IX83. The area of
each identified tumours was measured in all sections using FIJI and volume was
calculated by section thickness and taking gap sections into account. Kruskal–Wallis
test was performed to evaluate if the tumour size is significantly different from any
group to another (p= 0.0009). Post hoc the Dunn’s multiple comparisons test was
performed to identify which groups are significant from each other.
In addition, the effect of change of genotype on estimates volume was
determined by encoding genotype as an ordered factor (Mutantf/f < Mutantf/+ <
LATS1/2 cKO) and fitting a linear mixed effects model with animal as the random
effect using the function glmmPQL from the MASS package with the call
“glmmPQL(vol ~ geno, random= ~1|animal, “gaussian”)” diagnostic plots from
lm(vol ~ geno/animal) indicate that normality of residuals and heteroscedasticity
were reasonable assumptions but the mixed effects function was used for
hypothesis testing to account for “proper” nesting of animals within genotypes. The
quadratic term for genotype was non-significant (p= 0.8764).
Statistical analysis and reproducibility. Statistical analysis was performed using
GraphPad Prism 7 software, R 3.3.1 or R 3.5.1 using statistical tests as indicated in
the text. Statistical significance was visualised as: ns= not significant (p > 0.05),
*= p < 0.05, **= p < 0.01, ***= p < 0.001, ****= p < 0.0001.
All immunostaining experiments have been done using three mice and
representative images have been chosen for figures. For TEM, which has been
conducted on two animals due to the resource limitations; all features (microvilli,
tight junctions) observed in LATS1/2 cKO mice have been found throughout the
tumours in both mice.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
mRNA sequencing of nlsYAP5SA brains generated in this study have been deposited in
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO) under GSE147961 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE147961]. The quantitative proteomics (TMT) data set of nlsYAP5SA brains is
deposited in Pride under PXD018131. The YAP1-MAMDL1 and C11orf95-RELA gene
expression data to determine YAP1/RELA specificity referenced in our study is from
Pajtler et al. Supplementary Data 657. The paediatric brain tumour gene expression data
set used in Supplementary Fig. 6e is from58 deposited at NCBI GEO database and are
publicly accessible under accession number GSE50161. The data set used for cell type
association was taken from Sharma et al. Supplementary Data 8 and 1561.
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